White paper bolsters ctDNA as potential 'early endpoint' in cancer approvals
Regulatory NewsMary Ellen Schneider
BiologicsBiotechnologyClinical TrialsNorth AmericaPharmaceuticalsProduct LifecycleRegulatory NewsMary Ellen SchneiderBiologicsBiotechnologyClinical TrialsNorth AmericaPharmaceuticalsProduct Lifecycle